The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia

Authors

  • Muhammad Begawan Bestari Division of Gastroentero-Hepatology, Department of Internal Medicine Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Eka Surya Nugraha Division of Gastroentero-Hepatology, Department of Internal Medicine Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Siti Aminah Abdurachman Division of Gastroentero-Hepatology, Department of Internal Medicine Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung

DOI:

https://doi.org/10.24871/21120207-11

Keywords:

DAA, daclatasvir, sofosbuvir, HCV, pangenotypic regiment

Abstract

Background: Direct-acting antivirals (DAAs) have altered the prognosis of hepatitis C virus (HCV) disease but its access is limited by socioeconomic factors. Generic DAAs with lower prices were available in Indonesia in 2016. The aim of this study was to determine the efficacy of generic daclatasvir-sofosbuvir.

Method: We performed an observational study from January to December 2016 in a tertiary care center in Bandung, Indonesia. Data were obtained from medical registry. All study subjects received oral daclatasvir (60 mg, once daily) and sofosbuvir (400 mg, once daily) for 12 weeks for noncirrhotic chronic HCV patients and 24 weeks for cirrhotic chronic HCV patients. The main endpoint criterion was sustained virologic response at post-treatment week 12 (SVR12).

Results: We enrolled 32 subjects (20 noncirrhotic, 12 cirrhotic). All noncirrhotic subjects (eighteen were previously untreated patients) and cirrhotic subjects (all were previously untreated patients) achieved SVR12 of 100%. These high rates of SVR12 were observed in all patients with HCV infection regardless of the genotype. ALT normalization was achieved in all patients 12 weeks after therapy. The most common adverse events were fatigue and nausea.

Conclusion: Once-daily oral generic daclatasvir-sofosbuvir showed good efficacy and safety. Furthermore, it yielded a high rate of SVR among patients infected with HCV of all genotypes.

Downloads

Published

2020-07-26

How to Cite

Bestari, M. B., Nugraha, E. S., & Abdurachman, S. A. (2020). The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 21(1), 7–11. https://doi.org/10.24871/21120207-11

Issue

Vol. 21 No. 1 (2020): VOLUME 21, NUMBER 1, April 2020

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).